<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PROGUANIL HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PROGUANIL HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children up to 11 weeks (body-weight up to 6 kg)</strong><br/>
                25 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 3&#8211;11 months (body-weight 6&#8211;9 kg)</strong><br/>
                50 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 1&#8211;3 years (body-weight 10&#8211;16 kg)</strong><br/>
                75 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 4&#8211;7 years (body-weight 16&#8211;25 kg)</strong><br/>
                100 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 8&#8211;12 years (body-weight 25&#8211;45 kg)</strong><br/>
                150 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 13&#8211;17 years (body-weight 46 kg and above)</strong><br/>
                200 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Benefit of prophylaxis in malaria outweighs risk.</p><p>Adequate folate supplements should be given to mother.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Use half normal dose if estimated glomerular filtration rate 20&#8211;60 mL/minute/1.73m<sup>2</sup>.</p><p>Use one-quarter normal dose on alternate days if estimated glomerular filtration rate 10&#8211;20 mL/minute/1.73m<sup>2</sup>.</p><p>Use one-quarter normal dose once weekly if estimated glomerular filtration rate less than 10 mL/minute/1.73m<sup>2</sup>.</p><p>Increased risk of haematological toxicity.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>100&#8239;mg once daily if eGFR 20&#8211;60&#8239;mL/minute/1.73m<sup>2</sup>.</p><p>50&#8239;mg on alternate days if eGFR 10&#8211;20&#8239;mL/minute/1.73m<sup>2</sup>.</p><p>50&#8239;mg once weekly if eGFR less than 10&#8239;mL/minute/1.73m<sup>2</sup>. </p><p>Increased risk of haematological toxicity.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Constipation, diarrhoea, mild gastric intolerance,
              </p>
              <p>
                <strong>veryRare:</strong> Cholestasis, hair loss, skin reactions, vasculitis,
              </p>
              <p>
                <strong>notKnown:</strong> Mouth ulcers, stomatitis,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Tablet may be crushed and mixed with food such as milk, jam, or honey just before administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Warn travellers about <b>importance</b> of avoiding mosquito bites, <b>importance</b> of taking prophylaxis regularly, and <b>importance</b> of immediate visit to doctor if ill within 1 year and <b>especially</b> within 3 months of return.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>





      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Proguanil doses in BNF Publications may differ from those in product literature.</p>
            </section>
      </section>








      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria. </p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PROGUANIL HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP76488"><a href="../medicinalForm/PHP76488.html" data-target="#PHP76488" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
